Iron infusion is a procedure in which iron is delivered to your body intravenously, meaning into a vein through a needle. This method of delivering medication or supplementation is also known as an intravenous (IV) infusion. Iron infusions are usually prescribed by doctors to treat iron deficiency anemia.
Iron is one of the most important mineral present inside the human body. It carries oxygen throughout the body via the blood, which is further utilized by cells and tissue to get energy for all vital biological processes. Moreover, deficiency of iron leads to severe health problems, such as anemia and also affects mental or other memory functions in youths. To overcome this problem, oral iron supplements are recommended to maintain the iron level in the body. However, in some cases, oral administrations are not capable of maintaining the iron level in the body. For these cases, IV iron therapy is used to as part of which iron is directly injected inside the body with a needle through a vein.
The global Intravenous (IV) Iron Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intravenous (IV) Iron Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Intravenous (IV) Iron Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Intravenous (IV) Iron Drugs in these regions.
This research report categorizes the global Intravenous (IV) Iron Drugs market by top players/brands, region, type and end user. This report also studies the global Intravenous (IV) Iron Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Market size by Product
Market size by End User
Gynecology & Obstetrics
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global Intravenous (IV) Iron Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Intravenous (IV) Iron Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Intravenous (IV) Iron Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Intravenous (IV) Iron Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Intravenous (IV) Iron Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Intravenous (IV) Iron Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.